On February 3, Beijing time, Gileads science market soared 22%, reporting that Gilead, an American pharmaceutical company, was found to be effective against the new coronavirus.
After the opening of the US stock market, the share price rose 8.67% to US $68.68 per share, with a market value of US $86.8 billion. The stock closed up 5% with a total market value of about $84 billion.
Public information shows that Gilead Sciences, Inc. is famous for antiviral drugs in the industry, known as the apple of the pharmaceutical industry. It has listed a variety of anti HIV (HIV) and HCV (hepatitis C) drugs, and Tamiflu is also from the company.
Gilead is also a company that has experienced great ups and downs in the past 10 years. Its most famous drugs are harnovi and sovaldi, the drugs that conquer hepatitis C. In 2015, these two drugs brought Gilead $19.1 billion in revenue, of which harnovi is the second largest super heavyweight drug in the world.
However, after the peak period of 2015, the price of hepatitis C drugs with extremely high prices was also reduced under the double pressure of commercial insurance and low-income patients, coupled with the impact of Indian drug imitation, and the halo of magic drug of hepatitis C was no longer there. Since 2016, Geelys share price has fallen behind the growth of S & P market.
According to the news, Gilead
New type of coronavirus pneumonia can be treated by drugs under research
Gilead sciences remarkable performance in the secondary market is mainly due to a news on January 31.
On January 31, the New England Journal of Medicine (NEJM) published several papers on 2019-ncov cases online, one of which introduced the diagnosis and treatment process of the first confirmed case in the United States and the clinical manifestations of its experimental treatment with Geminid scientific research drug, remdesivir (gs-5734), as a sympathic drug. After treatment, the patient showed rapid remission.
Its reported that radcevir, which shows special effects on 2019-ncov, is phosphorylated from compound gs-441524 and can significantly inhibit RNA dependent RNA synthetase (RdRp), which is a broad-spectrum antiviral drug under research of Gilead science company.
The principle of inhibition, popularly speaking, is to prevent the gene composition of the virus when the virus RNA replicates and mixes into the newly synthesized RNA single chain of the virus.
In fact, Gilead developed redcevir to treat the Ebola virus, but it didnt go on because it didnt get better results in four randomized trials.
In 2012, Gilead found that the key compound gs-441524 had certain antiviral activity against hepatitis C virus, dengue virus, influenza A virus, parainfluenza virus and SARS can, and achieved good results in the test on cats. Because there is RdRp in Ebola virus and in coronavirus, it is also possible to inhibit coronavirus.
The good news was soon realized in the companys secondary market price. After the news that the first patient in the United States got better using redceway on January 31, Gilead sciences share price immediately rose 3% after hours.
Redceway is not here yet
Approval of listing in any country
In terms of the progress of research and development, in mid December last year, the New England Journal of Medicine published the results of phase 2 clinical trials of redcevir, which has completed phase 2 clinical trials of Ebola virus.
The clinical safety of Gilead phase I and phase II is completed overseas, said one senior medical industry insider. Because it belongs to a special period at present, there is no problem that it can directly enter the clinical stage of three-stage effectiveness in China. And it also has an example of effective data overseas, that is to say, security data should be complete. At least prove that the drug is safe for long-term use.
However, it is worth noting that merdad parsey, the global chief medical officer of Geely, said in a statement released on February 1, Beijing time that radecivir is a drug under development by Geely, which has not yet been approved for listing in any country, and its safety and effectiveness have not been confirmed.
In vitro and animal models, redacivir has been proved to be active against the viral pathogens of SARS and mers. They also belong to coronavirus, and are very similar to 2019-ncov in structure. The clinical data of emergency use of redacivir in the treatment of Ebola virus infected patients is limited.
Application for clinical trial of Radcliffe
Accepted by SFDA
Since redacivir is surprisingly effective in the treatment of new crown pneumonia, will it be used in this epidemic in China?
Yesterday, February 2, the official website of the drug evaluation center (CDE) of the State Food and drug administration showed that the clinical trial application of redacivir was accepted by the State Food and drug administration. According to the acceptance documents, the registered enterprise is the Institute of medicine of Gilead science and Chinese Academy of Medical Sciences.
Also yesterday, China Japan Friendship Hospital announced in its official wechat that it is taking the lead in the clinical research of redacivir in treating 2019 ncov new coronavirus in the epidemic area of Wuhan.
According to reports, Cao Bin, director of respiratory and Critical Medicine Department of China Japan Friendship Hospital, was responsible for the clinical research of redceway. This clinical trial will begin on February 3 and end on April 27. The trial will directly span the phase II clinical study, and will be included in the phase III clinical trial of 270 patients with mild and moderate new crown pneumonia.
In fact, unapproved drugs can sometimes be put into use or tested in an emergency, if the health department believes that the drug can help patients who lack better treatment. This phase 3 clinical trial is to verify the efficacy in mild to moderate patients, and the results are expected to be obtained within one month.
According to Liu Yuling, a researcher of the Institute of medicine of the Chinese Academy of Medical Sciences and a new drug evaluation member of the State Food and drug administration, said in an interview, in the extraordinary period of fighting against the epidemic, if the special affairs office of the State Food and Drug Administration speeds up the examination and approval, redacivir may only conduct 2300 clinical trials in China, and it is expected to obtain import approval in one or two months at the earliest. However, for a new drug under development, it usually needs to go through the clinical phase I, phase II and phase III trials, at least thousands of trials before it can be officially approved. The normal approval process should be at least half a year in theory.
As redceway has become the most concerned drug in the battle of pneumonia, a number of domestic listed pharmaceutical companies have announced that they are approaching and seeking cooperation with Gilead.
A few days ago, it was reported that Yongtai technology is seeking to cooperate with Geely in the future procurement of intermediates of the drug radcevir under research. On February 3, Yongtai technology said on the interactive platform that the company has involved in the production of drugs and intermediates related to Wuhan new crown pneumonia.
According to the public information, Yongtai science and technology business includes medicine, pesticide and electronic chemicals, mainly providing customized production, R & D and technical services for relevant enterprises of international giants. Pharmaceutical chemicals products mainly include fluorine-containing intermediates of cardiovascular drugs, diabetes drugs, psychotropic drugs, anti infective drugs and antiviral drugs, as well as the production of pharmaceutical raw materials and preparations Sale.
As of September 30, 2019, the operating revenue of Yongtai technology is 2.668 billion yuan, and the net profit attributable to the shareholders of the parent company is 318 million yuan, which is 20.23% lower than that of last year, and the basic earnings per share is 0.36 yuan. Yongtai science and technology announced that recently, the company learned that the drug remdesivir (redesivir) under research of geelide company can be used to treat pneumonia caused by new coronavirus infection. The company is actively engaged with geelide company and other downstream customers to seek possible cooperation opportunities. However, there is still uncertainty about whether the cooperation can be reached in this engagement, and the clinical trial and drug approval of the downstream customers are under research There is uncertainty and it will take a certain time. Please pay attention to the investment risk. In addition, there are a number of pharmaceutical companies in China are also seeking to discuss cooperation with Gilead in the research of redcevir. Source: editor in charge of China Fund News: Yang bin_nf4368
As of September 30, 2019, the operating revenue of Yongtai technology is 2.668 billion yuan, and the net profit attributable to the shareholders of the parent company is 318 million yuan, which is 20.23% lower than that of last year, and the basic earnings per share is 0.36 yuan.
Yongtai science and technology announced that recently, the company learned that the drug remdesivir (redesivir) under research of geelide company can be used to treat pneumonia caused by new coronavirus infection. The company is actively engaged with geelide company and other downstream customers to seek possible cooperation opportunities. However, there is still uncertainty about whether the cooperation can be reached in this engagement, and the clinical trial and drug approval of the downstream customers are under research There is uncertainty and it will take a certain time. Please pay attention to the investment risk.
In addition, there are a number of pharmaceutical companies in China are also seeking to discuss cooperation with Gilead in the research of redcevir.